Following a 61 percent decrease from 2017 levels, funding for treatment as prevention (TasP) totaled US$2.2 million in 2018. Philanthropic funding increased slightly but public sector investment decreased by 68 percent, from US$5.3 million in 2017 to US$1.7 million in 2018. This decrease is linked directly to the completion of the CDC-funded Botswana Combination Prevention project, which had been ongoing since 2013.
The efficacy of TasP as an HIV prevention strategy has been proven in multiple large-scale trials such as HPTN 052, PARTNER, Opposites Attract, and PARTNER 220. This likely explains the sharp decline in R&D investment for TasP since 2015.
For more, read the full report.